Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12336997 | 0.83 | KDM4E (0.47) | MEN1KMT2AGAAMAPTRAB9A | |
| SCHEMBL248683 | 0.79 | ELANE (0.50) | MEN1KMT2ALMNAGAA | |
| SCHEMBL2772549 | 0.75 | NPC1 (0.52) | KMT2ALMNAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL15641907 | 0.74 | ALDH1A1 (0.43) | MEN1KMT2AMAPTHDAC3HDAC6 | |
| SCHEMBL65489 | 0.73 | CACNA1C (0.42) | CA1CA2 | |
| SCHEMBL4113139 | 0.70 | ELANE (0.43) | LMNASMN1; SMN2CA1CA2 | |
| SCHEMBL14243750 | 0.70 | CYP1A2 (0.55) | MEN1KMT2AMAPTRAB9ACYP1A2 | |
| SCHEMBL19692262 | 0.70 | ALDH1A1 (0.33) | — | |
| SCHEMBL236001 | 0.70 | ALDH1A1 (0.33) | — | |
| SCHEMBL17372301 | 0.70 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2931917-B1 | PRIMERS WITH MODIFIED PHOSPHATE AND BASE IN ALLELE-SPECIFIC PCR | ROCHE DIAGNOSTICS GMBH (DE) | 2017-04-05 | — | — | EP | claimed |
| EP-2931917-A1 | PRIMERS WITH MODIFIED PHOSPHATE AND BASE IN ALLELE-SPECIFIC PCR | Roche Diagnostics GmbH (DE) | 2015-10-21 | — | — | EP | claimed |
| US-20140170650-A1 | Primers with Modified Phosphate and Base in Allele-Specific PCR | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2014-06-19 | — | — | US | claimed |
| WO-2014090837-A1 | PRIMERS WITH MODIFIED PHOSPHATE AND BASE IN ALLELE-SPECIFIC PCR | ROCHE DIAGNOSTICS GMBH (DE) | 2014-06-19 | — | — | WO | claimed |
| EP-2510118-B1 | PREFERENTIAL AMPLIFICATION OF MRNA OVER DNA USING CHEMICALLY MODIFIED PRIMERS | ROCHE DIAGNOSTICS GMBH (DE) | 2013-10-09 | — | — | EP | claimed |
| EP-2510118-A2 | PREFERENTIAL AMPLIFICATION OF MRNA OVER DNA USING CHEMICALLY MODIFIED PRIMERS | Roche Diagniostics GmbH (DE) | 2012-10-17 | — | — | EP | claimed |
| US-20110312040-A1 | Preferential Amplification of mRNA Over DNA Using Chemically Modified Primers | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2011-12-22 | — | — | US | claimed |
| WO-2011069676-A2 | PREFERENTIAL AMPLIFICATION OF MRNA OVER DNA USING CHEMICALLY MODIFIED PRIMERS | ROCHE DIAGNOSTICS GMBH (DE) | 2011-06-16 | — | — | WO | claimed |
| EP-2931917-B1 | PRIMERS WITH MODIFIED PHOSPHATE AND BASE IN ALLELE-SPECIFIC PCR | ROCHE DIAGNOSTICS GMBH (DE) | 2017-04-05 | — | — | EP | disclosed |
| US-9382581-B2 | Primers with modified phosphate and base in allele-specific PCR | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| EP-2931917-A1 | PRIMERS WITH MODIFIED PHOSPHATE AND BASE IN ALLELE-SPECIFIC PCR | Roche Diagnostics GmbH (DE) | 2015-10-21 | — | — | EP | disclosed |
| US-20140170650-A1 | Primers with Modified Phosphate and Base in Allele-Specific PCR | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2014090837-A1 | PRIMERS WITH MODIFIED PHOSPHATE AND BASE IN ALLELE-SPECIFIC PCR | ROCHE DIAGNOSTICS GMBH (DE) | 2014-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312040-A1 | Preferential Amplification of mRNA Over DNA Using Chemically Modified Primers | RNGTT, NSUN2, RNMT | MEN1 2501/4885KMT2A 1772/4885LMNA 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.